Evidence map›Paper›PMID 35122124›Full record

ArticleVirchows Archiv : an international journal of pathology2022

T1 bladder carcinoma with variant histology: pathological features and clinical significance.

Antonio Lopez-Beltran, Ana Blanca, Alessia Cimadamore, Rodolfo Montironi, Rafael J Luque, Metka Volavšek, Liang Cheng

Abstract read
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Antonio Lopez-BeltranDepartment of Morphological Sciences, University of Cordoba Medical School, Cordoba, Spain. em1lobea@uco.es.ORCID http://orcid.org/0000-0003-3161-8164
Ana BlancaMaimonides Biomedical Research Institute of Cordoba, E-14004, Cordoba, Spain.
Alessia CimadamoreInstitute of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy.ORCID http://orcid.org/0000-0001-5981-3514
Rodolfo MontironiInstitute of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy.ORCID http://orcid.org/0000-0003-3938-610X
Rafael J LuqueUGC Anatomía Patológica, Hospital Universitario de Jaén, Jaén, Spain.ORCID http://orcid.org/0000-0002-9808-784X
Metka VolavšekInstitute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.ORCID http://orcid.org/0000-0002-2878-4877
Liang ChengDepartments of Pathology and Laboratory Medicine and Urology, School of Medicine, Indiana University, Indianapolis, IN, USA.ORCID http://orcid.org/0000-0001-6049-5293

Funding

Instituto de Salud Carlos III PI17/01981
6 · The paper itself

Abstract

The aim of the study was to stratify high-grade T1 (HGT1) bladder urothelial carcinoma into risk categories based on the presence of variant histology when compared to conventional urothelial carcinoma. The clinicopathological features of 104 HGT1 cases of urothelial carcinoma of the bladder with variant histology present in 34 (37%) were assessed. The endpoint of the study was disease-free survival and cancer-specific survival. Overall, variant histology was identified as a significant predictor of disease-free survival (P = 0.035). The presence of any specific variant histology (squamous, glandular, micropapillary, nested, microcystic, inverted growth, villous-like, basaloid, and lymphoepithelioma-like) was identified as a significant predictor of disease-free survival (P = 0.008) and cancer-specific survival (P = 0.0001) in HGT1 bladder cancer. Therefore, our results support including micropapillary HGT1 urothelial carcinoma within the aggressive high-risk category, as suggested by some recent clinical guidelines, but also favor nested, glandular, and basaloid to be placed in the high-risk category due to their potential of aggressive, life-threatening behavior and their limited response to bacillus Calmette-Guerin therapy. Conversely, the low-risk category would include urothelial carcinomas with squamous, inverted growth, or microcystic morphology, all with limited life-threatening potential and good response to current therapy. A very low-risk category would finally include patients whose tumors present villous-like or lymphoepithelioma-like morphology. In conclusion, our findings support the value of reporting the variant histology as a feature of variable aggressiveness in HGT1 urothelial carcinoma of the bladder.

Indexed as

Carcinoma, PapillaryCarcinoma, Squamous CellCarcinoma, Transitional CellUrinary Bladder NeoplasmsFemaleHumansMaleUrinary BladderBiomarkerBladderStagingT1 urothelial carcinomaVariant histology

Identifiers

PMID35122124
PMCPMC9033727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.